R. Gilliver

发表

Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.

M. Alavi, G. Dore, L. Degenhardt, 2021, The International journal on drug policy.

Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.

C. Stedman, P. Read, B. Conway, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.

P. Read, G. Dore, I. van Beek, 2017, The International journal on drug policy.

Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study

P. Read, G. Dore, J. Grebely, 2022, Viruses.

Treatment adherence and support for people who inject drugs taking direct‐acting antiviral therapy for hepatitis C infection

P. Read, G. Dore, R. Gilliver, 2019, Journal of viral hepatitis.

Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort

Jessica R. Ackerman, P. Read, G. Dore, 2022, Journal of viral hepatitis.

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

P. Read, G. Dore, M. Weltman, 2020, Health science reports.

Hepatitis C virus testing, liver disease assessment and direct‐acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study

P. Read, G. Dore, C. Treloar, 2019, Journal of viral hepatitis.

The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptions.

S. Lenton, S. Nielsen, N. Lintzeris, 2022, Drug and alcohol review.

Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.

P. Read, G. Dore, J. Grebely, 2023, The International journal on drug policy.

Preparing for a syndemic: incorporating opioid overdose management into routine care for people who inject drugs initiating hepatitis C treatment

P. Read, R. Gilliver, J. Kearley, 2020, Internal medicine journal.

The role of repeat training in participants undertaking take home naloxone interventions.

S. Nielsen, N. Lintzeris, Llewellyn Mills, 2020, medRxiv.

Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.

S. Lenton, S. Nielsen, P. Haber, 2019, Drug and alcohol review.

IS REPEAT TRAINING NEEDED FOR THN?

S. Nielsen, L. Monds, M. Harrod, 2020 .

Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low‐threshold primary health‐care opioid agonist treatment program

P. Read, R. Gilliver, K. Chronister, 2019, Drug and alcohol review.

Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.

P. Read, G. Dore, I. van Beek, 2017, The International journal on drug policy.